Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Picankibart (IBI112) in Psoriasis Patients Switching from Biologics
NCT05970978Phase 2Completed
- Sponsor
- Innovent Biologics
- Start
- Aug 2023
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of picankibart in plaque psoriasis, sponsored by Innovent Biologics. Started Aug 2023; status: completed.
02
Drugs
picankibart
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05970978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05970978.